8-K: CARGO Therapeutics Halts Firi-Cel Study, Announces Workforce Reduction to Extend Cash Runway

CARGO Therapeutics discontinues its FIRCE-1 Phase 2 study, reduces workforce by 50%, and expects to extend its cash runway to mid-2028.

Summary

• CARGO Therapeutics has decided to discontinue the FIRCE-1 Phase 2 study of firicabtagene autoleucel (firi-cel).
• The company is reducing its workforce by approximately 50% as a result of this decision.
• CARGO will continue to advance CRG-023 to Phase 1 proof-of-concept data and its allogeneic platform to lead vector candidate selection while evaluating strategic options.
• These actions, along with other expense reductions, are expected to extend the company's cash runway to mid-2028.
• CARGO anticipates incurring expenses between $31 million and $37 million related to the discontinuation, primarily in the first quarter of 2025.
• This includes $4 million to $5 million for severance and termination costs, $20 million to $22 million for contract termination costs, and $7 million to $10 million to wind down the firi-cel clinical development program.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the discontinuation of the clinical trial and workforce reduction, although the extension of the cash runway is a positive aspect.

Positives

• The company expects to extend its cash runway to mid-2028.
• CARGO will continue to advance CRG-023 to Phase 1 proof-of-concept data and its allogeneic platform to lead vector candidate selection while evaluating strategic options.

Negatives

• The company is discontinuing the FIRCE-1 Phase 2 study of firi-cel.
• A 50% workforce reduction is planned.
• CARGO anticipates incurring $31 million to $37 million in expenses related to the discontinuation.

Risks

• The charges that the Company expects to incur in connection with the plan and related workforce reduction are subject to a number of assumptions, and actual results may differ materially.
• The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the plan and related workforce reduction.
• The company's ability to obtain necessary capital to fund its clinical programs is a risk.
• Clinical and preclinical development is a lengthy and expensive process with uncertain outcomes.
• The company relies on third-party suppliers and manufacturers, including CROs.

Future Outlook

The company will continue to advance CRG-023 to Phase 1 proof-of-concept data and its allogeneic platform to lead vector candidate selection while evaluating strategic options. The company expects its cash runway to extend to mid-2028.

Industry Context

The CAR T-cell therapy space is highly competitive and requires significant capital investment. Discontinuing a clinical trial and reducing workforce are not uncommon in the biotech industry when faced with challenging data or financial constraints. Companies like CARGO are constantly evaluating their pipelines and making strategic decisions to optimize resource allocation.

Comparison to Industry Standards

• Many biotech companies in the CAR T-cell therapy space, such as Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead), have faced similar challenges in clinical development.
• Workforce reductions and pipeline prioritization are common strategies employed by biotech companies to manage cash flow and focus on the most promising assets.
• The expected restructuring charges of $31 million to $37 million are within the typical range for companies undergoing similar restructuring activities.

Stakeholder Impact

• Shareholders will be impacted by the discontinuation of the clinical trial and the potential impact on the company's valuation.
• Employees will be impacted by the workforce reduction.
• Patients who were potential candidates for firi-cel will be impacted by the discontinuation of the clinical trial.
• Suppliers and contractors may be impacted by the contract terminations.

Next Steps

• Advance CRG-023 to Phase 1 proof-of-concept data.
• Advance the allogeneic platform to lead vector candidate selection.
• Evaluate strategic options.
• Implement the workforce reduction.
• Wind down the firi-cel clinical development program.

Key Dates